

Jan Dijkstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4060839/publications.pdf>

Version: 2024-02-01

64
papers

1,977
citations

218677

26
h-index

265206

42
g-index

70
all docs

70
docs citations

70
times ranked

2560
citing authors

#	ARTICLE	IF	CITATIONS
1	Breaking Entry-and Species Barriers: LentiBOOST® Plus Polybrene Enhances Transduction Efficacy of Dendritic Cells and Monocytes by Adenovirus 5. <i>Viruses</i> , 2022, 14, 92.	3.3	6
2	A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKK β -Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 785231.	4.8	9
3	Network- and systems-based re-engineering of dendritic cells with non-coding RNAs for cancer immunotherapy. <i>Theranostics</i> , 2021, 11, 1412-1428.	10.0	8
4	T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8679.	4.1	3
5	A Chimeric IL-15/IL-15R α Molecule Expressed on NF κ B-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10227.	4.1	5
6	BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11951.	4.1	8
7	Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 746359.	3.7	3
8	CARs: Beyond T Cells and T Cell-Derived Signaling Domains. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3525.	4.1	19
9	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. <i>Pharmaceutics</i> , 2020, 12, 92.	4.5	46
10	Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance. <i>Cancers</i> , 2019, 11, 1198.	3.7	46
11	Curatopes Melanoma: A Database of Predicted T-cell Epitopes from Overly Expressed Proteins in Metastatic Cutaneous Melanoma. <i>Cancer Research</i> , 2019, 79, 5452-5456.	0.9	3
12	CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2764.	4.1	20
13	Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA. <i>Frontiers in Immunology</i> , 2019, 10, 2.	4.8	8
14	CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities—Merits and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5942.	4.1	38
15	NF- κ B activation triggers NK-cell stimulation by monocyte-derived dendritic cells. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989162.	3.2	20
16	Autophagic degradation of lamins facilitates the nuclear egress of herpes simplex virus type 1. <i>Journal of Cell Biology</i> , 2019, 218, 508-523.	5.2	36
17	Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. <i>Human Gene Therapy</i> , 2018, 29, 547-558.	2.7	29
18	The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T cell functionality for further clinical development towards the potential use in immunotherapy of melanoma. <i>Experimental Dermatology</i> , 2018, 27, 769-778.	2.9	51

#	ARTICLE	IF	CITATIONS
19	BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 289.	4.1	16
20	The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2365.	4.1	53
21	Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy. <i>EMBO Molecular Medicine</i> , 2017, 9, 135-136.	6.9	3
22	Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins. <i>Methods in Molecular Biology</i> , 2017, 1499, 165-178.	0.9	27
23	RNA-transfection of β 2-microglobulin T cells with a chimeric antigen receptor or an α 1/2 T-cell receptor: a safer alternative to genetically engineered α 1/2 T cells for the immunotherapy of melanoma. <i>BMC Cancer</i> , 2017, 17, 551.	2.6	87
24	Proteomic Response of Human Umbilical Vein Endothelial Cells to Histamine Stimulation. <i>Proteomics</i> , 2017, 17, 1700116.	2.2	4
25	Preclinical evaluation of NF- κ B-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 451-464.	3.2	18
26	Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma. <i>Anticancer Research</i> , 2017, 37, 3243-3248.	1.1	5
27	Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation. <i>Journal of Immunology Research</i> , 2016, 2016, 1-17.	2.2	2
28	Combining a chimeric antigen receptor and a conventional T cell receptor to generate T cells expressing two additional receptors (<sc>TETAR</sc>s) for a multi-hit immunotherapy of melanoma. <i>Experimental Dermatology</i> , 2016, 25, 872-879.	2.9	27
29	Blockade of CCR7 leads to decreased dendritic cell migration to draining lymph nodes and promotes graft survival in low-risk corneal transplantation. <i>Experimental Eye Research</i> , 2016, 146, 1-6.	2.6	19
30	T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients. <i>Aids</i> , 2016, 30, 2149-2158.	2.2	5
31	Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and β 2-microglobulin T Cells. <i>PLoS ONE</i> , 2015, 10, e0131477.	2.5	16
32	Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	2.2	9
33	A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype. <i>Gene Therapy</i> , 2015, 22, 516-520.	4.5	4
34	Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions. <i>Cytotherapy</i> , 2015, 17, 989-1007.	0.7	17
35	Generation of CD8 ⁺ T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1323-1331.	3.4	20
36	Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1623-1635.	4.2	39

#	ARTICLE	IF	CITATIONS
37	Human Adenovirus-Specific \hat{I}^3/\hat{I}' and CD8 ⁺ T Cells Generated by T-Cell Receptor Transfection to Treat Adenovirus Infection after Allogeneic Stem Cell Transplantation. PLoS ONE, 2014, 9, e109944.	2.5	23
38	Concurrent interaction of DCs with CD4 ⁺ and CD8 ⁺ T cells improves secondary CTL expansion: It takes three to tango. European Journal of Immunology, 2014, 44, 3543-3559.	2.9	32
39	Triggering of NF- κ B in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy. European Journal of Immunology, 2014, 44, 3413-3428.	2.9	25
40	Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. Journal of Immunotoxicology, 2014, 11, 328-336.	1.7	65
41	A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunology, Immunotherapy, 2014, 63, 999-1008.	4.2	40
42	CD8 ⁺ T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?. Cancer Immunology, Immunotherapy, 2013, 62, 1769-1780.	4.2	12
43	Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes. Immunobiology, 2013, 218, 1392-1401.	1.9	45
44	Nonviral RNA Transfection to Transiently Modify T Cells with Chimeric Antigen Receptors for Adoptive Therapy. Methods in Molecular Biology, 2013, 969, 187-201.	0.9	44
45	Vaccination with Antigen-Transfected, NKT Cell Ligand-Loaded, Human Cells Elicits Robust <i>In Situ</i> Immune Responses by Dendritic Cells. Cancer Research, 2013, 73, 62-73.	0.9	37
46	Just One Position-Independent Lysine Residue Can Direct MelanA into Proteasomal Degradation following N-Terminal Fusion of Ubiquitin. PLoS ONE, 2013, 8, e55567.	2.5	10
47	Strong and sustained effector function of memory- versus naïve-derived <i>T</i> cells upon <i>T</i> -cell receptor RNA transfer: Implications for cellular therapy. European Journal of Immunology, 2012, 42, 3442-3453.	2.9	15
48	Autocrine TNF Is Critical for the Survival of Human Dendritic Cells by Regulating BAK, BCL-2, and FLIPL. Journal of Immunology, 2012, 188, 4810-4818.	0.8	21
49	Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection. PLoS ONE, 2012, 7, e31210.	2.5	101
50	HIV-1 mRNA electroporation of PBMC: A simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients. Journal of Immunological Methods, 2012, 380, 40-55.	1.4	5
51	Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies. International Journal of Hyperthermia, 2011, 27, 591-603.	2.5	67
52	Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes. Blood, 2011, 118, 5174-5177.	1.4	14
53	Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood, 2010, 116, 2277-2285.	1.4	111
54	A fast and robust method to clone and functionally validate T-cell receptors. Journal of Immunological Methods, 2009, 346, 45-54.	1.4	25

#	ARTICLE	IF	CITATIONS
55	Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. <i>Gene Therapy</i> , 2009, 16, 596-604.	4.5	105
56	Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 467-477.	4.2	33
57	A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. <i>Melanoma Research</i> , 2008, 18, 73-84.	1.2	18
58	Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA. <i>Aids</i> , 2008, 22, 1577-1582.	2.2	10
59	Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection. <i>Journal of Immunotherapy</i> , 2007, 30, 663-674.	2.4	51
60	A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1132-1141.	4.2	95
61	An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: Implications for tumor antigen detection and amplification. <i>Journal of Immunological Methods</i> , 2006, 313, 119-128.	1.4	17
62	Generation of an Optimized Polyvalent Monocyte-Derived Dendritic Cell Vaccine by Transfecting Defined RNAs after Rather Than before Maturation. <i>Journal of Immunology</i> , 2005, 174, 3087-3097.	0.8	133
63	INTERFERON- γ INCREASES THE EXPRESSION OF GLYCOSYLATED CD95 IN B-LEUKEMIC CELLS: AN INDUCIBLE MODEL TO STUDY THE ROLE OF GLYCOSYLATION IN CD95-SIGNALING AND TRAFFICKING. <i>Cytokine</i> , 2002, 18, 98-107.	3.2	12
64	Carnosol-induced apoptosis and downregulation of Bcl-2 in B-lineage leukemia cells. <i>Cancer Letters</i> , 2001, 170, 33-39.	7.2	74